Shares of Evolent Health Inc (NYSE:EVH) ended Friday session in red amid volatile trading. The shares closed down -0.74 points or -3.20% at $22.41 with 60.31 million shares getting traded. Post opening the session at $22.60 the shares hit an intraday low of $22.20 and an intraday high of $22.88 and the price vacillated in this range throughout the day. The company has a market cap of $1.31 billion and the numbers of outstanding shares have been calculated to be 60.31 million shares.
On Aug. 4, 2016 Evolent Health Inc (EVH) and St. Luke’s Health Partners announced that they have entered into a definitive agreement for a multi-year operating partnership. The collaboration between the two organizations will guide the development and execution of a value-based care strategy for improving the health of patients across the care delivery network of St. Luke’s Health System, the largest locally-owned health system in the state of Idaho.
“We partnered with Evolent due to the experience of their team, their proven record of measurable outcomes and the cultural alignment of both organizations,” said St. Luke’s Chief Physician Executive Dr. George Beauregard. “Transitioning to value-based care models is challenging work and requires strong partners. We are confident that this partnership will provide a foundation to transform health care for people throughout the region we serve.”
The partnership between St. Luke’s and Evolent will initially focus on supporting several capitated payment models to achieve clinical and financial quality targets. St. Luke’s will also support lives under value-based arrangements by implementing Evolent’s IdentifiSM technology platform, advanced predictive modeling, physician reporting and workflow tools, and risk adjustment and analytics support for highly effective clinical programs.
“We are excited to formalize our partnership with St. Luke’s Health Partners to further its vision for delivering higher quality, lower cost care for patients across Idaho,” said Evolent Chief Executive Officer Frank Williams. “The teams at St. Luke’s and Evolent are truly aligned in the belief that the key to success lay in fostering provider accountability for health outcomes of individual patients and entire populations—and that to achieve that vision, providers must be empowered with tools and resources to lead the transformation. We are thrilled to be selected as St. Luke’s long-term operating partner and we are looking forward to working collaboratively to engage physicians and patients in a new model of care.”
Shares of Mobileye NV (NYSE:MBLY) ended Friday session in red amid volatile trading. The shares closed down -1.46 points or -2.98% at $47.47 with 218.85 million shares getting traded. Post opening the session at $48.56 the shares hit an intraday low of $47.35 and an intraday high of $48.75 and the price vacillated in this range throughout the day. The company has a market cap of $10.10 billion and the numbers of outstanding shares have been calculated to be 218.85 million shares.
On Aug. 23, 2016 Mobileye (MBLY) and Delphi Automotive PLC (DLPH) announced a partnership to jointly develop a complete SAE Level 4/5 automated driving solution. The program will result in an end-to-end production-intent fully automated vehicle solution, with the level of performance and functional safety required for rapid integration into diverse vehicle platforms for a range of customers worldwide. The partners’ CSLP platform will be demonstrated in combined urban and highway driving at the 2017 Consumer Electronics Show in Las Vegas and production ready for 2019.
Mobileye is the world leader in computer vision systems, mapping, localization and machine learning focused on the automotive domain. Delphi is a world leader in automated driving software, sensors and systems integration. Working together, the two companies will co-develop the market’s first turnkey Level 4/5 automated driving solution.
The automated driving solution will be based on key technologies from each company. These include Mobileye’s EyeQ® 4/5 System on a Chip (SoC) with sensor signal processing, fusion, world view generation and Road Experience Management (REM™) system, which will be used for real time mapping and vehicle localization. Delphi will incorporate automated driving software algorithms from its Ottomatika acquisition, which include the Path and Motion Planning features, and Delphi’s Multi-Domain Controller (MDC) with the full camera, radar and LiDAR suite. In addition, teams from both companies will develop the next generation of sensor fusion technology as well as the next generation human-like “driving policy.” This module combines Ottomatika’s driving behavior modeling with Mobileye’s deep reinforcement learning in order to yield driving capabilities necessary for negotiating with other human drivers and pedestrians in complex urban scenes.
“The Mobileye and Delphi relationship started in 2002 with the implementation of what was one of the most advanced active safety systems of the time. Our long history together is key to the success of this ambitious endeavor,” said Professor Amnon Shashua, Mobileye Chairman and Chief Technology Officer. “Our partnership with Delphi will accelerate the time to market and enable customers to adopt Level 4/5 automation without the need for huge capital investments, thereby creating a formidable advantage for them.”